
    
      The study was terminated early and the pediatric development of serelaxin in the treatment of
      acute heart failure (AHF) discontinued, following the results of the phase III study
      RELAX-AHF-2 (CRLX030A2301/NCT01870778) study in adult patients with AHF. Whilst no new safety
      concerns associated with serelaxin were observed, the study in adults did not meet either of
      its primary endpoints
    
  